Brazil’s health regulator cancels Indian Covaxin vaccine clinical trial

The agency had suspended trials on Friday after being notified by Bharat that it had terminated its partnership with Brazilian Precisa Medicamentos.

RIO DE JANEIRO, BRAZIL - The Brazilian health regulatory agency (ANVISA) on Monday (26) permanently cancelled clinical trials in the country of Indian Covid-19 Covaxin vaccine, after the laboratory responsible for the immunizer, Bharat Biotech, broke ties with its representative in Brazil.

"The decision was made after a technical assessment that the end of Precisa's authorization to represent the vaccine in Brazil invalidates compliance with the regulations that govern the conduction of clinical trials of vaccines in the country," said ANVISA in a statement.

The agency suspended Covaxin clinical studies on Friday after being informed by Bharat of the . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?